News Release

December 19, 2016

Neovasc Regains Compliance with NASDAQ Listing Requirements


VANCOUVER, Dec. 19, 2016 /CNW/ – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) announced today that the Company has regained compliance with the listing requirements of The NASDAQ Stock Market LLC ("Nasdaq").

As previously reported, on July 5, 2016, Neovasc received a letter from Nasdaq notifying the Company that it was not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

On December 19, 2016, Neovasc received notification from Nasdaq stating that since the closing bid price of the Company’s common shares had been greater than US$1.00 per share for the last 10 consecutive business days, from December 5, 2016 to December 16, 2016, Neovasc was in compliance with Listing Rule 5550(a)(2) and this matter is now closed.

About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the U.S. and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the U.S., Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit:

SOURCE Neovasc Inc.